Subpressor Dose Asymmetric Dimethylarginine Modulates Renal Function in Humans through Nitric Oxide Synthase Inhibition

@article{Kielstein2004SubpressorDA,
  title={Subpressor Dose Asymmetric Dimethylarginine Modulates Renal Function in Humans through Nitric Oxide Synthase Inhibition},
  author={J. Kielstein and S. Simmel and S. Bode-B{\"o}ger and H. Roth and H. Schmidt-Gayk and H. Haller and D. Fliser},
  journal={Kidney and Blood Pressure Research},
  year={2004},
  volume={27},
  pages={143 - 147}
}
Increased blood concentrations of the endogenous nitric oxide (NO) synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to high blood pressure and to cardiovascular mortality. We evaluated the effects of a subpressor ADMA dose on NO production, renal hemodynamics, sodium handling and active renin and noradrenalin plasma concentrations in 12 healthy subjects (age 26 ± 1 year) using a double-blind placebo-controlled study design. Infusion of ADMA caused a significant decrease in… Expand
Effects of asymmetric dimethylarginine (ADMA) infusion in humans
Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.
Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
...
1
2
3
...